Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy For Treatment Of Solid Tumors Expressing NTSR1
Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy For Treatment Of Solid Tumors Expressing NTSR1
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.